NASDAQ:AERI
Delisted
Aerie Pharmaceuticals Stock News
$15.25
+0 (+0%)
At Close: Feb 17, 2023
Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
01:47pm, Wednesday, 28'th Apr 2021
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
06:30am, Wednesday, 28'th Apr 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
07:30am, Wednesday, 07'th Apr 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie (AERI) Up 11.8% Since Last Earnings Report: Can It Continue?
12:41pm, Saturday, 27'th Mar 2021
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark
11:23am, Monday, 01'st Mar 2021
Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.
Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q4 2020 Results - Earnings Call Transcript
01:35am, Friday, 26'th Feb 2021
Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q4 2020 Results - Earnings Call Transcript
Aerie Pharmaceuticals (AERI) Reports Q4 Loss, Tops Revenue Estimates
06:58pm, Thursday, 25'th Feb 2021
Aerie (AERI) delivered earnings and revenue surprises of -5.33% and 13.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
07:30am, Monday, 22'nd Feb 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2020 Results - Earnings Call Transcript
02:53am, Sunday, 08'th Nov 2020
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2020 Results - Earnings Call Transcript
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido On Q3 2020 Results - Quick Version Earnings Call Transcript
08:29pm, Thursday, 05'th Nov 2020
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido On Q3 2020 Results - Quick Version Earnings Call Transcript
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries
03:00am, Wednesday, 28'th Oct 2020
OSAKA, Japan & DURHAM, N.C.--(BUSINESS WIRE)--Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered in
